KYMR Kymera Therapeutics Inc

Price (delayed)

$47.35

Market cap

$2.13B

P/E Ratio

N/A

Dividend/share

N/A

EPS

N/A

Enterprise value

$2.09B

Highlights
Kymera Therapeutics's quick ratio has increased by 13% QoQ
KYMR's debt is down by 2.9% since the previous quarter
The equity has contracted by 3% from the previous quarter

Key stats

What are the main financial stats of KYMR
Market
Shares outstanding
45.03M
Market cap
$2.13B
Enterprise value
$2.09B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.71
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
N/A
EBIT
N/A
EBITDA
N/A
Free cash flow
N/A
Per share
EPS
N/A
Free cash flow per share
N/A
Book value per share
$6.14
Revenue per share
N/A
TBVPS
$10.4
Balance sheet
Total assets
$464.55M
Total liabilities
$189.31M
Debt
$17.47M
Equity
$275.25M
Working capital
$230.65M
Liquidity
Debt to equity
0.06
Current ratio
3.09
Quick ratio
3.05
Net debt/EBITDA
N/A
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
N/A
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KYMR stock price

How has the Kymera Therapeutics stock price performed over time
Intraday
-0.65%
1 week
-6.33%
1 month
15.88%
1 year
N/A
YTD
-23.63%
QTD
21.85%

Financial performance

How have Kymera Therapeutics's revenue and profit performed over time
Revenue
N/A
Gross profit
N/A
Operating income
N/A
Net income
N/A
Gross margin
N/A
Net margin
N/A

Growth

What is Kymera Therapeutics's growth rate over time

Valuation

What is Kymera Therapeutics stock price valuation
P/E
N/A
P/B
7.71
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The equity has contracted by 3% from the previous quarter

Efficiency

How efficient is Kymera Therapeutics business performance

Dividends

What is KYMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KYMR.

Financial health

How did Kymera Therapeutics financials performed over time
The total assets is 145% more than the total liabilities
Kymera Therapeutics's quick ratio has increased by 13% QoQ
The current ratio has increased by 13% since the previous quarter
KYMR's debt is 94% smaller than its equity
The equity has contracted by 3% from the previous quarter
KYMR's debt is down by 2.9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.